Many new potent beta-lactam antibiotics have been developed, but the increased incidence of resistance of Pseudomonas aeruginosa to these antibiotics is still a serious problem. It indicates the importance of evaluating new antibiotics that show no cross resistance with beta-lactam antibiotics for the treatment of P. aeruginosa infections.
Mureidomycins, novel peptidylnucleoside antibiotics produced by Streptomyces flavidovirens, are selective and potent antipseudomonal antibiotics (3) . They are composed of four structurally related components, designated A, B, C, and D (4) , that have low toxicity and are effective against P. aeruginosa infections in mice (5) . In a previous paper, we reported that mureidomycin A (MRD) induced spheroplast formation followed by cell lysis of P. aeruginosa at the MIC. In this paper, we report that MRD is a structurally new type of inhibitor of bacterial peptidoglycan synthesis.
MATERIALS AND METHODS Bacteria. P. aeruginosa SANK 75775 was grown in Trypto-soy broth (Eiken) at 37°C with vigorous shaking. Ether-treated cells were prepared from early-log-phase cells by the procedure of Vosberg and Hoffmann-Berling (19) .
Preparation of unlabeled and 14C-labeled UDP-MurNAc- 
RESULTS
Inhibition of peptidoglycan synthesis and lipid-intermediate formation.
As it was supposed that MRD would inhibit peptidoglycan synthesis of P. aeruginosa from the results reported in a previous study (5) , an in vitro peptidoglycansynthesizing system was constructed, using ether-treated P. aeruginosa cells as an enzyme source. It is well-known that precursors of peptidoglycan synthesis, such as UDPMurNAc-pentapeptide and UDP-GlcNAc, are permeable in ether-treated cells (9, 10) . The UDP-MurNAc-pentapeptidedependent incorporation of UDP-[14C]GlcNAc into a 5% TCA-insoluble fraction was increased in a time-dependent manner and inhibited by tunicamycin, ristocetin, and ampicillin, indicating that peptidoglycan synthesis could be monitored by this system (Table 1) . In this system, MRD also inhibited the incorporation of [14C]GlcNAc into a 5% TCAinsoluble fraction at concentrations less than those required to cause cell lysis or spheroplast formation in the organism. Approximately 0.5 p.g of MRD per ml was required for 50% inhibition, although the MIC of MRD for this organism was 1.56 p.g/ml. Mureidomycins B, C, and D also inhibited peptidoglycan synthesis to almost the same extent. To measure the effect on lipid-intermediate formation, the reaction mixture was extracted at pH 4.2 with n-butanol.
The incorporation of UDP-[14C]GlcNAc into a solventextractable fraction was inhibited by MRD and tunicamycin to the same extent as that of the 5% TCA-insoluble fraction (Table 2) . Ristocetin also inhibited this incorporation at a high concentration, but in contrast, a low concentration of ristocetin and ampicillin did not inhibit but rather increased incorporation into the solvent-extractable fraction. These results were in accordance with the known mechanism of actions of antibiotics; that is, tunicamycin inhibits the transfer of MurNAc-pentapeptide (17, 20) , ristocetin transglycosylation (2), and ampicillin cross linkage formation (14) . It is also supposed that MRD would inhibit the transfer of MurNAcpentapeptide to an endogenous lipid carrier or the addition of GlcNAc to the lipid-bound MurNAc-pentapeptide.
Inhibition of phospho-MurNAc-pentapeptide translocase. Transfer of MurNAc-pentapeptide from UDP to a lipid carrier is catalyzed by phospho-MurNAc pentapeptide translocase (15) . The effect of MRD on this enzyme was directly examined by using UDP-MurNAc-[14C]Ala-pen- and 87% at concentrations of 1 and 0.1 jig/ml, respectively (Table 3) . Tunicamycin also inhibited this reaction, but neither ristocetin nor ampicillin inhibited it, even at a concentration of 100 jig/ml. The concentration of MRD required for 50% inhibition was calculated to be about 0.05 ,ug/ml. Therefore, it was suggested that translocase was the primary target of MRD.
Effect on other steps of peptidoglycan synthesis. To determine whether MRD inhibits the steps of peptidoglycan synthesis after translocase, ether-treated cells were preincubated with only UDP-MurNAc-pentapeptide to accumulate lipid-bound MurNAc-pentapeptide, and then peptidoglycan synthesis was measured by adding to the reaction mixture UDP-[`4C]GlcNAc in the presence or absence of MRD (18) .
The rates of incorporation of UDP-['4C]GlcNAc into the solvent-extractable and TCA-insoluble fractions after preincubation were not significantly affected by MRD, even at 10 ,ug/ml, which inhibited incorporation more than 90% when preincubation was omitted (Table 4 ). This fact indicated that MRD did not inhibit the other enzymes, such as GlcNAc transglycosylase, peptidoglycan transglycosylase, or transpeptidase. (17, 20) , amphomycin (18) , and liposidomycin (7) have been reported to inhibit translocase, and they contain lipid moieties that are supposed to relate to their inhibitory activities. In fact, tunicamycin and amphomycin inhibit not only bacterial peptidoglycan synthesis but also mammalian polysaccharide synthesis (6, 16) which is also catalyzed through lipid-intermediate formation. However, MRD does not contain a lipid moiety, and it did not inhibit mammalian polysaccharide synthesis.
It is also interesting to note that MRD inhibited peptidoglycan synthesis in E. coli, which was intrinsically resistant to MRD, and in MRD-resistant P. aeruginosa mutants which were isolated spontaneously, to the same extent as P. aeruginosa in ether-treated system, although they were resistant to MRD concentrations of more than 200 ,ug/ml. It seems likely that the translocase in E. coli and in MRDresistant mutant of P. aeruginosa is sensitive to MRD. The resistance of these bacteria might derive from their permeability deficiency for MRD. The precise mechanism of the selective antipseudomonal activity of MRD remains to be determined.
